You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hormone Receptor Positive Malignant Neoplasm of Breast

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Hormone Receptor Positive Malignant Tumor of Breast Trial in United States (RAD140)

Completed
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • New Haven, Connecticut
  • +4 more
Aug 16, 2022

Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer Trial in Boston (MRI)

Recruiting
  • Breast Cancer
  • +5 more
  • MRI
  • Boston, Massachusetts
    Brigham and Women's Hospital
Dec 9, 2022

Breast Cancer Metastatic, Hormone Receptor Positive Malignant Tumor of Breast Trial in Spain (Combination, Rogaratinib +

Recruiting
  • Breast Cancer Metastatic
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Combination, Rogaratinib + palbociclib + fulvestrant
  • Hospitalet de Llobregat, Barcelona, Spain
  • +7 more
Feb 8, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Anastrozole,

Active, not recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +6 more
  • Atlanta, Georgia
  • +9 more
Oct 12, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Tumor

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +13 more
  • Bintrafusp Alfa
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

Comparison of the Breast Tumor Microenvironment

Recruiting
  • Triple Negative Breast Cancer
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Breast tissue collection
  • Blood sample collection
  • New York, New York
    Columbia University Irving Medical Center
Aug 18, 2021

Tumor Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer Trial in United States (XL102, Fulvestrant,

Recruiting
  • Neoplasm Malignant
  • +4 more
  • Atlanta, Georgia
  • +4 more
Apr 19, 2022

Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant

Withdrawn
  • Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
  • +3 more
  • (no location specified)
Oct 13, 2021

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Breast Cancer Trial in New Brunswick (U-13C-glucose)

Not yet recruiting
  • Breast Cancer
  • New Brunswick, New Jersey
  • +1 more
Feb 16, 2023

Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

Not yet recruiting
  • Breast Neoplasms
  • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
  • +2 more
Oct 23, 2023

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

Breast Cancer Female, Hormone Receptor Positive Malignant Tumor of Breast Trial in Worldwide (Palbociclib, Endocrine therapy)

Active, not recruiting
  • Breast Cancer Female
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Clayton, Australia
  • +24 more
Jan 5, 2022

Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)

Recruiting
  • Hormone Receptor-positive Breast Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian

Not yet recruiting
  • Hormone-receptor-positive Breast Cancer
  • +3 more
  • Aromatase inhibitor
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Apr 5, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

Recruiting
  • Early-stage Breast Cancer
  • +4 more
  • Trastuzumab and nelatinib
  • Trastuzumab and Parstuzumab
  • Guangzhou, China
    Sun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023

Musculoskeletal Syndrome Trial in Minneapolis (CBD-dominant, THC dominant)

Recruiting
  • Musculoskeletal Syndrome
  • Minneapolis, Minnesota
    University of Minnesota
Jun 28, 2023

HER2-positive Breast Cancer, Advanced Breast Cancer Trial in Phoenix, Miami, Boston (Prolonged Overnight Fasting,

Not yet recruiting
  • HER2-positive Breast Cancer
  • Advanced Breast Cancer
  • Prolonged Overnight Fasting
  • +2 more
  • Phoenix, Arizona
  • +2 more
Nov 8, 2023

Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Oct 10, 2022

Brain Metastases, HR+ Metastatic Breast Cancer Trial in Tampa (Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy)

Recruiting
  • Brain Metastases
  • HR+ Metastatic Breast Cancer
  • Stereotactic Radiosurgery (SRS)
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Nov 1, 2022

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ocala, Florida
    Ocala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • Tianjin, China
    Tianjin Cancer Hospital
Mar 28, 2023